>The question is whether the same kind of long term gain is seen with something that doesn't use the immune system.<
In HCV, I expect that long-term durability of SVR will be seen regardless of the treatment regimen that was responsible for achieving the SVR. In other words, I don’t subscribe to the notion that immune-system “reprogramming” plays a major role in preventing a relapse.
Market Data 
Markets 
AI
